192 related articles for article (PubMed ID: 37875869)
1. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in combination with FOLFOX chemotherapy as a first-line treatment for gastric cancer patients with peritoneal metastases: single-arm phase II study.
Luksta M; Bausys A; Bickaite K; Rackauskas R; Paskonis M; Luksaite-Lukste R; Ranceva A; Stulpinas R; Brasiuniene B; Baltruskeviciene E; Lachej N; Sabaliauskaite R; Bausys R; Tulyte S; Strupas K
BMC Cancer; 2023 Oct; 23(1):1032. PubMed ID: 37875869
[TBL] [Abstract][Full Text] [Related]
2. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) of peritoneal metastasis from gastric cancer: a descriptive cohort study.
Ellebæk SB; Graversen M; Detlefsen S; Lundell L; Fristrup CW; Pfeiffer P; Mortensen MB
Clin Exp Metastasis; 2020 Apr; 37(2):325-332. PubMed ID: 32002724
[TBL] [Abstract][Full Text] [Related]
3. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis.
Nadiradze G; Giger-Pabst U; Zieren J; Strumberg D; Solass W; Reymond MA
J Gastrointest Surg; 2016 Feb; 20(2):367-73. PubMed ID: 26511950
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Peritoneal Metastasis with Pressurized Intraperitoneal Aerosol Chemotherapy: Results from the Prospective PIPAC-OPC2 Study.
Graversen M; Detlefsen S; Ainsworth AP; Fristrup CW; Knudsen AO; Pfeiffer P; Tarpgaard LS; Mortensen MB
Ann Surg Oncol; 2023 May; 30(5):2634-2644. PubMed ID: 36602663
[TBL] [Abstract][Full Text] [Related]
5. No Renal Toxicity After Repeated Treatment with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Unresectable Peritoneal Metastasis.
Larbre V; Alyami M; Mercier F; Vantard N; Bonnefoy I; Opsomer MA; Villeneuve L; Bakrin N; Rioufol C; Glehen O; Kepenekian V
Anticancer Res; 2018 Dec; 38(12):6869-6875. PubMed ID: 30504403
[TBL] [Abstract][Full Text] [Related]
6. Pressurized IntraPeritoneal Aerosol Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer - study protocol for a randomized control trial.
Somashekhar SP; Ashwin KR; Rauthan A; Rohit KC
Pleura Peritoneum; 2019 Mar; 4(1):20180111. PubMed ID: 31198851
[TBL] [Abstract][Full Text] [Related]
7. Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis.
Di Giorgio A; Schena CA; El Halabieh MA; Abatini C; Vita E; Strippoli A; Inzani F; Rodolfino E; Romanò B; Pacelli F; Rotolo S
Surg Oncol; 2020 Sep; 34():270-275. PubMed ID: 32891341
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcome for Patients Managed with Low-Dose Cisplatin and Doxorubicin Delivered as Pressurized Intraperitoneal Aerosol Chemotherapy for Unresectable Peritoneal Metastases of Gastric Cancer.
Sindayigaya R; Dogan C; Demtröder CR; Fischer B; Karam E; Buggisch JR; Tempfer CB; Lecomte T; Ouaissi M; Giger-Pabst U
Ann Surg Oncol; 2022 Jan; 29(1):112-123. PubMed ID: 34611790
[TBL] [Abstract][Full Text] [Related]
9. PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Bakrin N; Tempfer C; Scambia G; De Simone M; Gabriel B; Grischke EM; Rau B
Pleura Peritoneum; 2018 Sep; 3(3):20180114. PubMed ID: 30911662
[TBL] [Abstract][Full Text] [Related]
10. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer.
Alyami M; Bonnot PE; Mercier F; Laplace N; Villeneuve L; Passot G; Bakrin N; Kepenekian V; Glehen O
Eur J Surg Oncol; 2021 Jan; 47(1):123-127. PubMed ID: 32561204
[TBL] [Abstract][Full Text] [Related]
11. Bidirectional Approach with PIPAC and Systemic Chemotherapy for Patients with Synchronous Gastric Cancer Peritoneal Metastases (GCPM).
Casella F; Bencivenga M; Brancato G; Torroni L; Ridolfi C; Puccio C; Alloggio M; Meloni F; Fusario D; Marrelli D; Giacopuzzi S; Roviello F; de Manzoni G
Ann Surg Oncol; 2023 Sep; 30(9):5733-5742. PubMed ID: 37270440
[TBL] [Abstract][Full Text] [Related]
12. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis.
Robella M; Vaira M; De Simone M
World J Surg Oncol; 2016 Apr; 14():128. PubMed ID: 27125996
[TBL] [Abstract][Full Text] [Related]
13. First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II).
Lurvink RJ; Rauwerdink P; Rovers KP; Wassenaar ECE; Deenen MJ; Nederend J; Huysentruyt CJR; van 't Erve I; Fijneman RJA; van der Hoeven EJRJ; Seldenrijk CA; Constantinides A; Kranenburg O; Los M; Herbschleb KH; Thijs AMJ; Creemers GM; Burger JWA; Wiezer MJ; Nienhuijs SW; Boerma D; de Hingh IHJT
BMJ Open; 2021 Mar; 11(3):e044811. PubMed ID: 33785492
[TBL] [Abstract][Full Text] [Related]
14. Randomized control trial comparing quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC) and intravenous chemotherapy.
Somashekhar SP; Ashwin KR; Rauthan CA; Rohit KC
Pleura Peritoneum; 2018 Sep; 3(3):20180110. PubMed ID: 30911661
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC).
Graversen M; Detlefsen S; Bjerregaard JK; Pfeiffer P; Mortensen MB
Clin Exp Metastasis; 2017 Jun; 34(5):309-314. PubMed ID: 28516306
[TBL] [Abstract][Full Text] [Related]
16. PIPAC EstoK 01: Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin (PIPAC C/D) in gastric peritoneal metastasis: a randomized and multicenter phase II study.
Eveno C; Jouvin I; Pocard M
Pleura Peritoneum; 2018 Jun; 3(2):20180116. PubMed ID: 30911659
[TBL] [Abstract][Full Text] [Related]
17. Concentrations of cisplatin and doxorubicin in ascites and peritoneal tumor nodules before and after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal metastasis.
Tempfer CB; Hilal Z; Dogan A; Petersen M; Rezniczek GA
Eur J Surg Oncol; 2018 Jul; 44(7):1112-1117. PubMed ID: 29753612
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with gastric cancer and peritoneal metastasis.
Javanbakht M; Mashayekhi A; Branagan-Harris M; Horvath P; Königsrainer A; Reymond MA; Yaghoubi M
Eur J Surg Oncol; 2022 Jan; 48(1):188-196. PubMed ID: 34479745
[TBL] [Abstract][Full Text] [Related]
19. Pressurized Intraperitoneal Aerosol Chemotherapy-Related Clinical Trials in the Treatment of Peritoneal Metastases.
Ukegjini K; Putora PM; Guidi M; Süveg K; Cihoric N; Widmann B; Steffen T
Oncology; 2021; 99(9):601-610. PubMed ID: 34265774
[TBL] [Abstract][Full Text] [Related]
20. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for rare gynecologic indications: peritoneal metastases from breast and endometrial cancer.
Rezniczek GA; Giger-Pabst U; Thaher O; Tempfer CB
BMC Cancer; 2020 Nov; 20(1):1122. PubMed ID: 33213407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
